Loading
A phase 2 trial of Dacarbazine in sarcomas, run by Philogen S.p.A., active and no longer recruiting.
Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma is a phase 2 interventional study registered as NCT04733183 by Philogen S.p.A., with 98 participants planned, started 2020-08-28 and due to reach its primary completion in 2025-12. Interventions recorded: Dacarbazine, onfekafusp alfa. Conditions listed: Soft Tissue Sarcoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Philogen S.p.A., Cytotoxic chemotherapy.
Shares Dacarbazine, Cytotoxic chemotherapy.
Shares Dacarbazine, Cytotoxic chemotherapy.
Shares Dacarbazine, Sarcomas (soft tissue, bone, GIST), Cytotoxic chemotherapy.
Shares Dacarbazine, Cytotoxic chemotherapy.
Shares Dacarbazine, Cytotoxic chemotherapy.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/